Gabelli Funds LLC Lowers Stake in Tenet Healthcare Corporation $THC

Gabelli Funds LLC decreased its position in shares of Tenet Healthcare Corporation (NYSE:THC) by 62.5% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 23,854 shares of the company’s stock after selling 39,681 shares during the quarter. Gabelli Funds LLC’s holdings in Tenet Healthcare were worth $4,501,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in THC. Triumph Capital Management acquired a new position in Tenet Healthcare in the third quarter valued at $25,000. Activest Wealth Management acquired a new stake in Tenet Healthcare in the 4th quarter worth about $26,000. Elyxium Wealth LLC purchased a new stake in Tenet Healthcare in the 4th quarter valued at about $29,000. Meeder Asset Management Inc. lifted its holdings in shares of Tenet Healthcare by 146.2% during the 4th quarter. Meeder Asset Management Inc. now owns 192 shares of the company’s stock worth $38,000 after acquiring an additional 114 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Tenet Healthcare in the second quarter worth approximately $35,000. Institutional investors and hedge funds own 95.44% of the company’s stock.

Tenet Healthcare Stock Up 7.8%

Shares of Tenet Healthcare stock opened at $262.36 on Wednesday. Tenet Healthcare Corporation has a twelve month low of $155.02 and a twelve month high of $262.68. The stock has a market cap of $22.60 billion, a price-to-earnings ratio of 10.12, a price-to-earnings-growth ratio of 1.37 and a beta of 1.27. The company has a current ratio of 1.41, a quick ratio of 1.35 and a debt-to-equity ratio of 2.00. The company has a fifty day moving average price of $187.59 and a 200 day moving average price of $198.22.

Tenet Healthcare (NYSE:THC) last released its quarterly earnings data on Friday, July 24th. The company reported $6.12 EPS for the quarter, beating the consensus estimate of $4.26 by $1.86. Tenet Healthcare had a return on equity of 26.76% and a net margin of 10.27%.The company had revenue of $6.04 billion for the quarter, compared to analyst estimates of $5.43 billion. During the same period last year, the company posted $4.02 earnings per share. The firm’s revenue was up 6.8% compared to the same quarter last year. Equities research analysts forecast that Tenet Healthcare Corporation will post 20.9 earnings per share for the current fiscal year.

More Tenet Healthcare News

Here are the key news stories impacting Tenet Healthcare this week:

• Positive Sentiment: Strong Q2 results and improved outlook: Tenet beat analyst expectations for both earnings and revenue, while raising its 2026 forecast. Performance was driven by solid same-facility growth and disciplined expense management, reinforcing the company’s operating momentum. Tenet Healthcare Tops Q2 Earnings Estimates, Raises 2026 Outlook
• Positive Sentiment: Analysts raise price targets: Truist increased its target to $290 from $270 and maintained a “buy” rating. Guggenheim raised its target to $283 from $242 and also rated the shares “buy.” The upgrades suggest analysts see further upside following the earnings beat and improved guidance. Analyst price-target updates
• Positive Sentiment: Growth-stock appeal: Zacks highlighted Tenet as a highly ranked growth stock, which could attract additional interest from growth, value and momentum-focused investors. Tenet Healthcare Is a Top-Ranked Growth Stock
• Neutral Sentiment: Mixed analyst signal: Robert W. Baird lifted its target sharply to $280 from $210 but retained a “neutral” rating, indicating improved valuation expectations without a full shift to a bullish stance. Analyst price-target update
• Negative Sentiment: Executive and director stock sales: EVP Paola M. Arbour sold 10,878 shares worth approximately $2.65 million, reducing her position by 37.14%. Director Christopher S. Lynch sold 3,837 shares worth about $934,000, cutting his ownership by 28.62%. Although these sales may be for personal or tax-related reasons, the sizable transactions could create a modest overhang for THC. Tenet Healthcare insider transaction filing

Analyst Ratings Changes

Several equities analysts recently commented on the stock. KeyCorp dropped their price target on shares of Tenet Healthcare from $250.00 to $225.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Guggenheim boosted their price objective on shares of Tenet Healthcare from $242.00 to $283.00 and gave the company a “buy” rating in a research note on Tuesday. Cantor Fitzgerald restated an “overweight” rating on shares of Tenet Healthcare in a report on Monday. Weiss Ratings cut Tenet Healthcare from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, June 2nd. Finally, Stephens restated an “overweight” rating and set a $285.00 price target on shares of Tenet Healthcare in a research note on Monday. Seventeen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Tenet Healthcare presently has a consensus rating of “Moderate Buy” and an average target price of $268.50.

Insider Buying and Selling

In related news, Director Christopher S. Lynch sold 3,837 shares of the business’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $243.44, for a total transaction of $934,079.28. Following the transaction, the director directly owned 9,568 shares of the company’s stock, valued at approximately $2,329,233.92. The trade was a 28.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Nadja West sold 3,000 shares of the stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $177.35, for a total transaction of $532,050.00. Following the completion of the sale, the director directly owned 24,805 shares of the company’s stock, valued at $4,399,166.75. This trade represents a 10.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 23,353 shares of company stock valued at $5,103,217. Insiders own 0.97% of the company’s stock.

Tenet Healthcare Company Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.